完整後設資料紀錄
DC 欄位語言
dc.contributor.authorLi, Chun-Hsienen_US
dc.contributor.authorBai, Yi-Lingen_US
dc.contributor.authorChen, Yu-Chieen_US
dc.date.accessioned2019-04-02T06:00:16Z-
dc.date.available2019-04-02T06:00:16Z-
dc.date.issued2018-01-01en_US
dc.identifier.issn2169-1401en_US
dc.identifier.urihttp://dx.doi.org/10.1080/21691401.2018.1438449en_US
dc.identifier.urihttp://hdl.handle.net/11536/148779-
dc.description.abstractEscherichia coli O157:H7 is a pathogen, which can generate Shiga-like toxins (SLTs) and cause hemolytic-uremic syndrome. Foodborne illness outbreaks caused by E. coli O157:H7 have become a global issue. Since SLTs are quite toxic, effective medicines that can reduce the damage caused by SLTs should be explored. SLTs consist of a single A and five B subunits, which can inhibit ribosome activity for protein synthesis and bind with the cell membrane of host cells, respectively. Pigeon ovalbumin (POA), i.e. a glycoprotein, is abundant in pigeon egg white (PEW) proteins. The structure of POA contains Gal-(14)-Gal-(14)-GlcNAc ligands, which have binding affinity toward the B subunit in SLT type-1 (SLT-1B). POA immobilized gold nanoparticles (POA-Au NPs) can be generated by reacting PEW proteins with aqueous tetrachloroauric acid in one-pot. The generated POA-Au NPs have been demonstrated to have selective trapping-capacity toward SLT-1B previously. Herein, we explore that POA-Au NPs can be used as protective agents to neutralize the toxicity of SLT-1 in SLT-1-infected model cells. The results show that the cells can be completely rescued when a sufficient amount of POA-Au NPs is used to treat the SLT-1-infected cells within 1h.en_US
dc.language.isoen_USen_US
dc.subjectShiga like toxin-1en_US
dc.subjectEscherichia coli O157:H7en_US
dc.subjectgold nanoparticlesen_US
dc.subjectpigeon egg whitesen_US
dc.subjectpigeon ovalbuminen_US
dc.subjectmicrocapsulesen_US
dc.subjectartificial cellsen_US
dc.subjecttargeted deliveryen_US
dc.titleInhibition of the lethality of Shiga-like toxin-1 by functional gold nanoparticlesen_US
dc.typeArticleen_US
dc.identifier.doi10.1080/21691401.2018.1438449en_US
dc.identifier.journalARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGYen_US
dc.citation.volume46en_US
dc.citation.issue1en_US
dc.contributor.department應用化學系zh_TW
dc.contributor.departmentDepartment of Applied Chemistryen_US
dc.identifier.wosnumberWOS:000457049400078en_US
dc.citation.woscount0en_US
顯示於類別:期刊論文